SONGDO, South Korea—Samsung’s drug-manufacturing arm is betting that the already-booming market for biologic drug ingredients will only get hotter, thanks to industry shifts sparked by the coronavirus pandemic. Key to that bet is a nearly $2 billion drugmaking plant that, when completed in 2022, will be the largest of its kind in the world. Dubbed the “Super Plant,” Samsung Biologics Co.’s fourth factory will have around 230,000 square meters of floor space, making it bigger than the company’s three existing plants combined...

Source: Wall Street Journal September 03, 2020 09:33 UTC